Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
about
N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin tPopulation pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitorsNelfinavir: an update on its use in HIV infection.Functional expression and localization of P-glycoprotein at the blood brain barrier.Pharmacological issues relating to viral resistance.Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitorsPharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy malesAge-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Clinical pharmacology and pharmacokinetics of amprenavir.Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady stateInitiating antiretrovirals during tuberculosis treatment: a drug safety review.Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome.Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant womenMinimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patientsLung cancer in HIV infected patients: facts, questions and challenges.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers.Oncologic complications of human immunodeficiency virus infection: changing epidemiology, treatments, and special considerations in the era of highly active antiretroviral therapy.Tipranavir: a new option for the treatment of drug-resistant HIV infection.Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives.Pharmacologic consideration for the use of antiretroviral agents in the elderly.Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer.Everted gut sac model as a tool in pharmaceutical research: limitations and applications.Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein.HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort StudyMay the drug transporter P glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function.Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report.Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.Effect of Danggui and Honghua on Cytochrome P450 1A2, 2C11, 2E1 and 3A1 mRNA Expression in Liver of Rats.Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
P2860
Q33370268-61E69BD1-253D-4887-8382-0183F03E7FD5Q33795052-118DD4CB-560E-4411-B9A6-75D5AAA44A94Q33807628-914700F9-508C-425E-A366-586F5097828AQ33864976-079505EF-FA5D-4647-8653-E4D8D38EDCACQ33897234-DBCAEA5E-0BC1-45BD-A80A-DF482B6EA7E7Q33960099-1A0F0D47-B930-4DA7-B8F1-9FC23907BB30Q33961792-9742D4D9-8253-4EA3-9888-BC721F53BC17Q33979580-FD4FD886-97F3-4A7C-84A0-FAAE1A8F12E1Q33981408-81BFA737-B2B5-4495-8A73-5CCA06D437FEQ34100187-2892E624-3F14-48C1-8345-7932A2F6BEC2Q34437996-319B357F-320A-4C9B-8936-4DCB867E64A1Q34509359-012CAB5F-9BDD-4F0D-BB15-5C4D80A4D7F3Q34510726-F8681A09-6C08-405B-94C1-BC1A1C42F1D7Q35043048-8A43E8A3-3DA2-418C-990A-682EBB747410Q35125760-AFFB5671-2D16-44A9-B84E-4F6B3074149BQ35444159-3DE1A8CC-190B-451D-BE48-33856ABD2935Q35547031-04F0235A-3232-4723-B561-2C72DCB6AC8AQ35547832-7BC6CCE5-EA4F-45E1-B6E6-D39AD1866235Q36024688-411A245E-492C-4A22-A65F-6500EB94E53BQ36237964-A8C21A18-14D4-4844-B512-05F179D1F939Q36376533-75A99DF9-958E-4AE1-9D81-B80C867B3C6EQ36593820-B05A2D39-E177-475E-A0D1-DA271172552BQ36693871-ECAA02E4-A4C0-469A-8A2B-9E963BCA8601Q36916096-CB4C58FC-013E-4C06-95E1-95F700FCE6ADQ37157697-5D6F7354-EAAD-4B32-BBE6-B01E5FA1E817Q37277510-4BAB42A1-8E57-45E0-AE64-E7E7468ADB58Q37740126-3708AAAB-CBF6-4655-9737-5EAEC8D24777Q37981723-C2C7EAFC-2F98-4E38-9F50-7D77E55883C6Q38261574-4547BA43-9B7B-459B-89DD-EA19535AD577Q39473480-B1B5C02D-109B-433E-BF56-021A2CD8025CQ40162203-4F91CA81-472A-4B7D-9F5B-4F23CB4326F1Q40707587-EC317CD1-D6F8-4EBC-88DE-B6F25632B1A7Q42729447-E356D7A5-C67B-48D5-80E2-81EFC2F09742Q43767922-58FFD038-153F-48D0-81E7-C6DB4CC788B5Q44117968-68D1DB3B-4AA8-43B9-B1B9-60023A863FCBQ44261692-29D57833-3E7D-496C-9307-6C27ED612BFEQ44606318-6E92E299-B62E-405B-8953-6E6B64515A10Q45741891-EA7D35FB-EC79-43DD-8886-C73FECF29571Q46504597-9A977870-F414-4196-B442-C704C6427DE3Q46698300-D0316462-72D6-4C0B-8BCB-1CC879666F6E
P2860
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Interaction of anti-HIV protea ...... P-gp) in human cultured cells.
@en
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein
@nl
type
label
Interaction of anti-HIV protea ...... P-gp) in human cultured cells.
@en
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein
@nl
prefLabel
Interaction of anti-HIV protea ...... P-gp) in human cultured cells.
@en
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein
@nl
P2093
P1476
Interaction of anti-HIV protea ...... P-gp) in human cultured cells.
@en
P2093
P304
P356
10.1097/00042560-199811010-00001
P407
P577
1998-11-01T00:00:00Z